Removing the barriers to effective AAV process development with next-generation analytical platforms
Today’s bioprocess workflows demand more efficiency than ever before. This is driving the need for greater improvements in analytical assay performance and instrument automation. This webinar will focus on the challenges around removing analytics as the bottleneck and sourcing the variability of analytical assays in AAV process development.
The development of next-generation analytical platforms has opened the door to improvements in assay throughput and reproducibility, providing researchers with more automated solutions for the assessment of viral vector identity, purity and stability. Discover how Dr Kiren Baines uses these technologies to meet increased throughput and safety demands for scaling AAV process development.
What will you learn?
- Learn how next-generation analytical platforms are helping to solve key AAV process development challenges
- Discover how analytical automation is helping to drive greater throughput and reproducibility in today’s bioprocess workflows
- Explore how improvements in analytical assay performance are providing critical precision and efficiency advantages in AAV process development
- Learn how analytical instrument automation provides critical process and workflow advantages for scaling AAV process development
- Overcoming today’s analytical challenges in AAV process development
Who may this interest?
- Pharmaceutical scientists
- Manufacturers
- Analytical development managers
- Quality control directors
- Cell and gene therapy analytical scientists
Speaker
Dr Kiren Baines
Analytics Team Leader
eXmoor Pharma Concepts (Bristol, UK)
Dr Kiren Baines is the analytics team lead at eXmoor Pharma Concepts. Kiren has over eight years of experience in analytical and assay development. Kiren has played an instrumental role in setting up the analytical department at eXmoor and is an expert in PCR techniques, immunoassays and flow cytometry. Prior to joining eXmoor, Kiren was an analytical scientist at Charles River Laboratories (UK). Kiren completed her Ph.D. from the University of Bristol in the field of autophagy, cell biology.
In association with
